Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. / Knoop, A; Andreasen, P A; Andersen, J A; Hansen, S; Laenkholm, A V; Simonsen, A C; Andersen, J; Overgaard, J; Rose, C.
I: British Journal of Cancer, Bind 77, Nr. 6, 03.1998, s. 932-40.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
AU - Knoop, A
AU - Andreasen, P A
AU - Andersen, J A
AU - Hansen, S
AU - Laenkholm, A V
AU - Simonsen, A C
AU - Andersen, J
AU - Overgaard, J
AU - Rose, C
PY - 1998/3
Y1 - 1998/3
N2 - The uPA-mediated pathway of plasminogen activation is central to cancer metastasis. Whether uPA and PAI-1 are related to local recurrence, metastatic spread or both is not clear. We present a retrospective study of 429 primary breast cancer patients with a median follow-up of 5.1 years, in which the levels of uPA and PAI-1 in tumour extracts were analysed by means of an enzyme-linked immunosorbent assay. The median values of uPA and PAI-1, which were used as cut-off points, were 4.5 and 11.1 ng mg(-1) protein respectively. The levels of uPA and PAI-1 were correlated with tumour size, degree of anaplasia, steroid receptor status and number of positive nodes. Patients with high content of either uPA or PAI-1 had increased risk of relapse and death. We demonstrated an independent ability of PAI-1 to predict distant metastasis (relative risk 1.7, confidence limits 1.22 and 2.46) and that neither uPA nor PAI-1 provided any information regarding local recurrence.
AB - The uPA-mediated pathway of plasminogen activation is central to cancer metastasis. Whether uPA and PAI-1 are related to local recurrence, metastatic spread or both is not clear. We present a retrospective study of 429 primary breast cancer patients with a median follow-up of 5.1 years, in which the levels of uPA and PAI-1 in tumour extracts were analysed by means of an enzyme-linked immunosorbent assay. The median values of uPA and PAI-1, which were used as cut-off points, were 4.5 and 11.1 ng mg(-1) protein respectively. The levels of uPA and PAI-1 were correlated with tumour size, degree of anaplasia, steroid receptor status and number of positive nodes. Patients with high content of either uPA or PAI-1 had increased risk of relapse and death. We demonstrated an independent ability of PAI-1 to predict distant metastasis (relative risk 1.7, confidence limits 1.22 and 2.46) and that neither uPA nor PAI-1 provided any information regarding local recurrence.
KW - Adult
KW - Aged
KW - Breast Neoplasms/enzymology
KW - Carcinoma, Intraductal, Noninfiltrating/enzymology
KW - Cell Differentiation
KW - Enzyme-Linked Immunosorbent Assay
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Lymph Nodes/pathology
KW - Lymphatic Metastasis
KW - Middle Aged
KW - Neoplasm Invasiveness
KW - Neoplasm Metastasis
KW - Plasminogen Activator Inhibitor 1/analysis
KW - Predictive Value of Tests
KW - Prognosis
KW - Receptors, Estrogen
KW - Receptors, Progesterone
KW - Risk Assessment
KW - Sensitivity and Specificity
KW - Statistics, Nonparametric
KW - Survival Analysis
KW - Time Factors
KW - Urokinase-Type Plasminogen Activator/analysis
U2 - 10.1038/bjc.1998.154
DO - 10.1038/bjc.1998.154
M3 - Journal article
C2 - 9528837
VL - 77
SP - 932
EP - 940
JO - The British journal of cancer. Supplement
JF - The British journal of cancer. Supplement
SN - 0007-0920
IS - 6
ER -
ID: 259933154